Modeling phospholipidosis induction: Reliability and warnings

Journal of Chemical Information and Modeling

Volumn 53, Issue 6, 2013, Pages 1436-1446

  Goracci, Laura ^a   Ceccarelli, Martina ^a   Bonelli, Daniela ^a   Cruciani, Gabriele ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DATABASE SYSTEMS; DISCRIMINANT ANALYSIS; DRUG INTERACTIONS; PHOSPHOLIPIDS;

DATA QUALITY; DATA SET; DRUG DISCOVERY; IN-SILICO MODELS; LAMELLAR INCLUSION; PARTIAL LEAST SQUARES DISCRIMINANT ANALYSES (PLSDA); SIDE EFFECT;

LEAST SQUARES APPROXIMATIONS;

DRUG; PHOSPHOLIPID;

BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; HUMAN; LYSOSOME; METABOLISM; ARTICLE;

COMPUTER SIMULATION; HUMANS; LYSOSOMES; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS;

EID: 84879566407     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400113t     Document Type: Article

References (55)

1. Halliwell, W. H. Cationic amphiphilic drug-induced phospholipidosis Toxicol. Pathol. 1997, 25, 53-60
2. Reasor, M. J.; Hastings, K. L.; Ulrich, R. G. Drug-induced phospholipidosis: issues and future directions Expert Opin. Drug Saf. 2006, 5, 567-83
3. Chatman, L. A.; Morton, D.; Johnson, T. O.; Anway, S. D. A strategy for risk management of drug-induced phospholipidosis Toxicol. Pathol. 2009, 37, 997-1005
4. Nelson, A. A.; Fitzhugh, O. G. Chloroquine: pathological changes observed in rats for two years had been fed various proportions Arch. Pathol. 1948, 45, 454-462
5. Nonoyama, T.; Fukuda, R. Drug-induced phospholipidosis-pathological aspects and its prediction J. Toxicol. Pathol. 2008, 21, 9-24
6. Kodavanti, U. P.; Mehendale, H. M. Cationic amphiphilic drugs and phospholipid storage disorder Pharmacol. Rev. 1990, 42, 327-54
7. Reasor, M. J.; Kacew, S. Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. 2001, 226, 825-30
8. Mortuza, G. B.; Neville, W. A.; Delaney, J.; Waterfield, C. J.; Camilleri, P. Characterisation of a potential biomarker of phospholipidosis from amiodarone-treated rats Biochim. Biophys. Acta 2003, 1631, 136-146
9. Morelli, J. K.; Buehrle, M.; Pognan, F.; Barone, L. R.; Fieles, W.; Ciaccio, P. J. Validation of an ex vivo screen for phospholipidosis using a high-content biology platform Cell Biol. Toxicol. 2006, 22, 15-27
10. Baronas, E. T.; Lee, J. W.; Alden, C.; Hsieh, F. Y. Biomarkers to monitor drug-induced phospholipidosis Toxicol. Appl. Pharmacol. 2007, 218, 72-78
11. Ploemen, J. P.; Kelder, J.; Hafmans, T.; van de Sandt, H.; van Burgsteden, J. A.; Saleminki, P. J.; van Esch, E. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis- inducing potential: A case study with structurally related piperazines Exp. Toxicol. Pathol. 2004, 55, 347-355
12. Tomizawa, K.; Sugano, K.; Yamada, H.; Horii, I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential J. Toxicol. Sci. 2006, 31, 315-324
13. Pelletier, D. J.; Gehlhaar, D.; Tilloy-Ellul, A.; Johnson, T. O.; Greene, N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential J. Chem. Inf. Model. 2007, 47, 1196-1205
14. Hanumegowda, U. M.; Wenke, G.; Regueiro-Ren, A.; Yordanova, R.; Corradi, J. P.; Adams, S. P. Phospholidosis as a function of basicity, liphophilicity and volume of distribution of compound Chem. Res. Toxicol. 2010, 23, 749-55
15. Fischer, H.; Atzpodien, E. A.; Csato, M.; Doessegger, L.; Lenz, B.; Schmitt, G.; Singer, T. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets J. Med. Chem. 2012, 55, 126-39
16. Kruhlak, N. L.; Choi, S. S.; Contrera, J. F.; Weaver, J. L.; Willard, J. M.; Hastings, K. L.; Sancilio, L. F. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models Toxicol. Mech. Methods 2008, 18, 217-27
17. Lowe, R.; Glen, R. C.; Mitchell, J. B. Predicting phospholipidosis using machine learning Mol. Pharmaceutics 2010, 7, 1708-14
18. Lowe, R.; Mussa, H. Y.; Nigsch, F.; Glen, R. C.; Mitchell, J. B. Predicting the mechanism of Phospholipidosis J. Cheminf. 2012, 26, 1186-1758
19. Sun, H.; Shahane, S.; Xia, M.; Austin, C. P.; Huang, R. Structure based model for the prediction of phospholipidosis induction potential of small molecules J. Chem. Inf. Model. 2012, 52, 1798-1805
20. Orogo, A. M.; Choi, S. S.; Minnier, B. L.; Kruhlak, N. L. Construction and consensus performance of (Q)SAR models for predicting phospholipidosis using a dataset of 743 compounds Mol. Inf. 2012, 31, 725-739
21. Vitovic, P.; Alakoskela, J. M.; Kinnunen, K. J. Assessment of drug-lipid complex formation by a high throughput Langmuir-Balance and correlation to phospholipidosis J. Med. Chem. 2008, 51, 1842-1848
22. Cruciani, G.; Crivori, P.; Carrupt, P. A.; Testa, B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach J. Mol. Struct.: THEOCHEM 2000, 503, 17-30
23. The VolSurf+ Manual available at http://www.moldiscovery.com/docs/vsplus/ (accessed February 1, 2012).
24. Mannhold, R.; Berellini, G.; Carosati, E.; Benedetti, P. Use of MIF-Based VolSurf Descriptors in Physicochemical and Pharmacokinetic Studies. In Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction; Cruciani, G., Ed.; Wiley-VCH: New York, 2006; Vol. 27, pp 173-196.
25. Crivori, P.; Cruciani, G.; Carrupt, P. A.; Testa, B. Predicting blood-brain barrier permeation from three-dimensional molecular structure J. Med. Chem. 2000, 43, 2204-16
26. Ottaviani, G.; Martel, S.; Carrupt, P. A. In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities J. Med. Chem. 2007, 50, 742-748
27. Berellini, G.; Springer, C.; Waters, N. J.; Lombardo, F. In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set J. Med. Chem. 2009, 52, 4488-4495
28. Berellini, G.; Waters, N. J.; Lombardo, F. In silico prediction of total human plasma clearance J. Chem. Inf. Model. 2012, 52 (8) 2069-2078
29. Milletti, F.; Storchi, L.; Sforna, G.; Cruciani, G. New and original pKa prediction method using grid molecular interaction fields J. Chem. Inf. Model. 2007, 47 (6) 2172-2181
30. Milletti, F.; Storchi, L.; Goracci, L.; Bendels, S.; Wagner, B.; Kansy, M.; Cruciani, G. Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series Eur. J. Med. Chem. 2010, 45, 4270-4279
31. Mingeot-Leclercq, M. P.; Tulkens, P. M. Aminoglycosides: nephrotoxicity Antimicrob. Agents Chemother. 1999, 43, 1003-1012
32. De Broe, M. E.; Guy, P.; Verpooten, G.; Roels, F.; Buyssens, N.; Wedeen, R.; Van Hoof, F.; Tulkens, P. Early effects of gentamicin, tobramycin, and amikacin on the human kidney Kidney Int. 1984, 25, 643-652
33. De Broe, M. E.; Giuliano, R. A.; Verpooten, G. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity Am. J. Med. 1986, 80, 115-118
34. Naritomi, Y.; Terashita, S.; Kagayama, A.; Sugiyama, Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro Drug Metab. Dispos. 2003, 31, 580-588
35. O'Brien, P.; Chan, K.; Silber, P. M. Human and animal hepatocytes in vitro with extrapolation in vivo Chem.-Biol. Interact. 2004, 150, 97-114
36. Van der Meer, M. J.; Hundt, H. K.; Müller, F. O. The metabolism of atropine in man J. Pharm. Pharmacol. 1986, 38, 781-784
37. Narang, P. K.; Crouthamel, W. G.; Carliner, N. H.; Fisher, M. L. Lidocaine and its active metabolites Clin. Pharmacol. Ther. 1978, 24, 654-662
38. Nickolson, V. J.; Wieringa, J. H.; van Delft, A. M. L. Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin Naunyn-Schmiedeberg's Arch. Pharmacol. 1982, 319, 48-55
39. Drug label for Inderal (propranolol hydrochloride). http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/016418s080,016762s017, 017683s008lbl.pdf (accessed February 1, 2012).
40. Drug label for Zoloft (sertraline hydrochloride). http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/19839s073,s081,20990s034s040lbl.pdf (accessed February 1, 2012).
41. Quaglino, D.; Ha, H. R.; Duner, E.; Bruttomesso, D.; Bigler, L.; Follath, F.; Realdi, G.; Pettenazzo, A.; Baritussio, A. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287, 438-447
42. Zhou, L.; Geraci, G.; Hess, S.; Yang, L.; Wang, J.; Argikar, U. Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug phospholipid complex formation in early drug discovery Anal. Chem. 2011, 83, 6980-6987
43. RDKit version 2013.03.1. http://www.rdkit.org (accessed Jan 2013).
44. Labute, P. A widely applicable set of descriptors J. Mol. Graphics Modell. 2000, 18, 464-477
45. Schwaha, R.; Ecker, G. F. Similarity-based descriptors-useful for classification of ABCB1 substrates? QSAR Comb. Sci. 2009, 28, 834-839
46. Moorthy, N. S. H. N.; Ramos, M. J.; Fernandes, P. A. RSC Adv. 2011, 1, 1126-1136
47. Soldani, P.; Pellegrini, A.; Gesi, M.; Lenzi, P.; Paparelli, A. Suramin-induced ultrastructural changes in the testis of albino rats Exp. Toxicol. Pathol. 1996, 48, 299-305
48. Constantopoulos, G.; Rees, S.; Cragg, B. G.; Barranger, G. A.; Brady, R. O. Suramin-induced storage disease. Mucopolysaccharidosis Am. J. Pathol. 1983, 113, 266-268
49. Cramer, C. T.; Ulrich, R. G. Cytotoxicity and lamellar body induction potential of a racemic benzamide antiarrhythmic compound and enantiomers in cultured rat hepatocytes Toxicol. In Vitro 1994, 5, 1083-1090
50. Whitehouse, L. W; Menzies, A.; Mueller, R.; Pontefract, R. Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole Toxicology 1994, 94, 81-95
51. Przybylak, K. R.; Cronin, M. T. D. In silico studies of the relationship between chemical structure and drug induced phospholipidosis Mol. Inf. 2011, 30, 415-429
52. Sora, D.; Udrescu, S.; David, V.; Medvedovici1, A. Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies Biomed. Chromatogr. 2007, 21, 1023-1029
53. Mazue, G.; Berthe, J.; Newmann, A. J.; Brunaud, M. A toxicologic evaluation of ethyl fluclozepate (CM 6912) Int. J. Clin. Pharmacol., Ther. Toxicol. 2010, 19, 453-72
54. Hruban, Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs Environ. Health Perspect. 1984, 55, 53-76
55. Unsicker, K.; Allan, I. J.; Newgreen, D. F. Extraneuronal effects of 6-hydroxydopamine and extraneuronal uptake of noradrenaline. In vivo and ex vivo studies on adrenocortical cells of lizards and rats Cell Tissue Res. 1976, 173, 45-69